Skip to main content
Equibles
PODD logo

PODD · Insulet Corp

Track PODD — free

Use PODD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PODD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$135.62 +3.93 (+2.98%) At close · Oct 5
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$9.44B
Shares
69.35M
Volume · Oct 5 1.94M Avg daily vol (3M) 1.66M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$131.69 Open$131.83 Day$128.01–132.53 52W close$130.47–346.36 Avg vol 30d1.8M Short int5.1M · 7.3% float · 3.2d Short vol40% Last earningsNov 4, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 5

Up next

Next earnings release
Nov 4, 2026 Announced · in 4 wks
Next earnings call
Nov 4, 2026 Scheduled · in 4 wks
Latest filing: 10-Q
filed Aug 5, 2026
Q2 2026 earnings call transcript
call held Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.05B
Trailing 12 months
Net income (TTM)
$375.30M
Trailing 12 months
Revenue growth YoY
+23.5%
Year over year
Operating margin
16.9%
Trailing 12 months
P / E (TTM)
24.7
Trailing earnings · reciprocal yield 4.0%
FCF yield
3.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.8%
Year over year · fewer shares
Price change (1Y)
-57.8%
Trailing year
Short interest
7.3%
Latest settlement · 3.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −32%
below
Price vs 50-day avg −9%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −13%
trailing
6-month return −33%
trailing
YTD return −54%
this year
Relative strength −46%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $145 › 200d $193 — 200d above 50d
Institutional flow Distributing
4 of 735 funds reported for Sep 30 · net -1.2K sh shares · +1 new
Insider flow Accumulating
Net +$162.2K over 90 days · 0% sells
Short interest Rising
7.33% of float · ▲ +14.3% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
735 holders — mid 3-yr range
Squeeze score 53
elevated · 0–100
Fundamentals
Excellent
Revenue growth +31%
Y/Y
Gross margin 72%
expanding
EPS growth −40%
Y/Y
Free cash flow $377.7M
Valuation P/E 25.5
below peers
Buyback $475.0M
authorized
Balance sheet $233.1M
net debt
Quant / Vol
risk profile
High
Volatility 45%
annualized · 1-yr
Max drawdown −62%
past year
ATR 3.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 5, 2026
Q3 2026
U.S. Omnipod Non-GAAP Initiated 14% – 16%
Total Omnipod Non-GAAP Initiated 18% – 20%
International Omnipod Non-GAAP Initiated 28% – 30%
Total Non-GAAP Initiated 17.5% – 19.5%
FY 2026
U.S. Omnipod Non-GAAP Initiated 17% – 19%
International Omnipod Non-GAAP Initiated 30% – 32%
Total Omnipod Non-GAAP Initiated 21% – 23%
Total Non-GAAP Initiated 20% – 22%
Adjusted EPS Growth Non-GAAP Initiated at least 30%
Guided vs delivered · last 1 settled
Revenue full year 2021
guided $1B
$1.1B Beat +9.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−32% Bearish
Price vs 50-day avg
−9% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $145 › 200d $193 — 200d above 50d
Institutional flow Distributing
4 of 735 funds reported for Sep 30 · net -1.2K sh shares · +1 new
Insider flow Accumulating
Net +$162.2K over 90 days · 0% sells
Short interest Rising
7.33% of float · ▲ +14.3% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
735 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $130 Now $132 · 1% Range high $346
vs 200-day avg -32% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $381.5M Six Months Ended June 30, 2026 —
Adjusted net income non-GAAP $115M Second Quarter 2026 —
GAAP → non-GAAP reconciliation
GAAP Net Income 95M
+20M Voluntary MDCs and related costs
-0.1M CFO transition costs
+0.2M Tax matters
= Adjusted Net Income 115M
Free cash flow non-GAAP $145.4M Six Months Ended June 30, 2026 —
International Omnipod Constant Currency Revenue Growth non-GAAP 38.4% Six Months Ended June 30, 2026 —
Non-GAAP Diluted Earnings per Share non-GAAP $3.08 Six Months Ended June 30, 2026 —
Non-GAAP Gross Profit non-GAAP $1.13B Six Months Ended June 30, 2026 —
Non-GAAP Operating Income non-GAAP $288M Six Months Ended June 30, 2026 —
Total Constant Currency Revenue Growth non-GAAP 22.7% Three Months Ended June 30, 2026 —
Total Omnipod Constant Currency Revenue Growth non-GAAP 28.1% Six Months Ended June 30, 2026 —
U.S. Omnipod Constant Currency Revenue Growth non-GAAP 24% Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PODD
Insulet Corp
this stock
$9.44B -53.7% +30.7% 25.5 7.3%
ABT
Abbott Laboratories
 $174.90B -22.2% +5.7% 28.1 1.1%
MDT
Medtronic plc
 $113.38B -10.1% +8.4% 21.8 1.3%
SYK
Stryker Corp
 $104.47B -21.6% +11.2% 28.2 2.0%
BSX
Boston Scientific Corp
 $63.59B -55.3% +12.5% 17.8 3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
736
% held
103.8%
Reported
4 of 735
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
696
View
Short & Settlement
Short Interest Rising
Shares short
5.1M
Days to cover
3.2d
Change
+634.8K sh
View
Short Volume
Short vol %
40%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
446
Value
$66.0K
As of
Aug 19, 2026
View
Off-Exchange
Off-exchange %
40.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$162.2K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Aug 18, 2026
View
Financials
Financials
Revenue (FY)
$2.7B
Net income (FY)
$247.1M
EPS diluted
$3.48
View
Buybacks
Authorized · 2 programs
$475.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 21, 2026
This year
20
View
Proposed Sales
Value
$59.9K
Shares
418
Filed
Jun 3, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 4, 2026
Last webcast
Sep 9, 2026
View
Investor Relations
Latest news
Insulet to Announce Third Quarter…
Published
Oct 1, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
PODD -3.3% -12.5% -33.4% +0.9% -53.7%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -3.0% -12.1% -45.6% +0.0% -66.5%

Capital returns

Buyback programs · 2 active · as of Feb 28, 2026
Authorized (total)
$475.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1145197 CUSIP 45784P101 13F (30d) 21 filings 16 filers Visit website Investor relations